New strategies for drug development;Neue strategien zur entwicklung von arzneimitteln

Berliner und Munchener Tierarztliche Wochenschrift

Volumn 117, Issue 7-8, 2004, Pages 276-287

  Veit, Michael ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Human immunodeficiency virus; Influenza virus; Membrane fusion; Neuraminidase inhibitors; Protease inhibitors; Protein kinase inhibitors; Structure based drug design

Indexed keywords

VETERINARY DRUG;

ANIMAL; DRUG DESIGN; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VETERINARY DRUGS;

HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS;

EID: 3342997926     PISSN: 00059366     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Anderson, A. C. (2003): The process of structure-based drug design. Chem. Biol. 10, 787-797.
2. Arai, M., D.D. Earl, J. K. Yamamoto (2002): Is AZT/3TC theraphy effective against FIV infection or immunopathogenesis? Vet. Immunol. Immunopathol. 85, 189-204.
3. Colman, P. M. (1994): Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 3, 1687-1696.
4. Dancey J., E. A. Sausville (2003): Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2, 296-313.
5. De Clercq, E. (2002): Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1, 13-25.
6. Doms, R. W., J. P. Moore (2000): HIV-1 Membrane Fusion: Targets of Opportunity. J. Cell. Biol. 151, F9-14.
7. Drews, J. (2000): Drug discovery: a historical perspective. Science 287, 1960-1964.
8. Druker B. J. (2002): Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21, 8541-8546.
9. Eckert D. M., P. S. Kim (2001): Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810.
10. Folkers, G., H. Kubinyi (1997): Der gezielte Weg zum Arzneimittel. Spektrum der Wissenschaft, Spezial 6, 17-27.
11. Gubareva, L. V., C. R. Penn, R. G. Webster (1995): Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212, 323-330.
12. Gubareva L. V., L. Kaiser, F. G. Hayden (2000): Influenza virus neuraminidase inhibitors. Lancet 355, 827-835.
13. Jahn, R., T. Lang, T. C. Südhof (2003): Membrane fusion. Cell 112, 519-533.
14. Lin, Y-C., Z. Beck, G. M. Morris, A. J. Olson, J. H. Elder (2003): Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J. Virol. 77, 6589-6600.
15. McCauley, J. W., L. A. Pullen, M. Forsyth, C. R. Penn, G. P. Thomas (1995): 4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus. Antiviral Res. 27, 179-186.
16. Medinas, R. J., D. M. Lambert, W. A. Tompkins (2002): C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J. Virol. 76, 9079-9086.
17. Oxford, J. S., P. Novelli, A. Sefton, R. Lambkin (2002): New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antivir. Chem. Chemother. 13, 205-217.
18. Plunkett, M. J., J. A. Ellmann (1997): Neue Wirkstoffe durch kombinatorische Chemie Spektrum der Wissenschaft, Spezial 6, 28-35.
19. Rott R., H. D. Klenk, Y. Nagai, M. Tashiro (1995): Influenza viruses, cell enzymes, and pathogenicity. Am. J. Respir. Crit. Care Med. 152, 16-19.
20. Skehel, J. J., D. C. Wiley (2000): Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569.
21. Veit, M. (1999): Molekularbiologie der Neurosekretion und ihre Hemmung durch Tetanus- und Botulinumtoxine. Berl. Münch. Tierärztl. Wochenschr. 112, 186-191.
22. Waalen, J (2001): Gleevec's Glory days. HHMI (Howard Hughes Medical Institute) Bulletin Dezember 2001, 10-15. unter http://www.hhmi.org/bulletin/ dec2001/gleevec/index.html.
23. Webby, R. J., R. G. Webster (2001): Emergence of influenza A viruses. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 1817-1828.
24. Webby, R. J., R. G. Webster (2003): Are We Ready for Pandemic Influenza? Science 302, 1519-1522.
25. Wlodawer A., J. Vondrasek (1998): Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27, 249-284.